Anti-Saccharomyces cerevisiae antibodies associate with phenotypes and higher risk for surgery in Crohn's disease: A meta-analysis

Digestive Diseases and Sciences

Volumn 57, Issue 11, 2012, Pages 2944-2954

  Zhang, Zhaoxia ^a   Li, Chen ^a   Zhao, Xinmei ^a   Lv, Chaolan ^a   He, Qiong ^a   Lei, Shan ^a   Guo, Yandong ^a   Zhi, Fachao ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Anti Saccharomyces cerevisiae antibody; Crohn's disease; Inflammatory bowel diseases; Systematic review and meta analysis

Indexed keywords

FUNGUS ANTIBODY; SACCHAROMYCES CEREVISIAE ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CROHN DISEASE; FOLLOW UP; GENETIC SUSCEPTIBILITY; META ANALYSIS; NONHUMAN; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; PUBLISHING; RISK FACTOR; SACCHAROMYCES CEREVISIAE; SENSITIVITY AND SPECIFICITY; SURGICAL RISK;

ANTIBODIES, FUNGAL; BIOLOGICAL MARKERS; CROHN DISEASE; HUMANS; PHENOTYPE; PROGNOSIS; RISK FACTORS; SACCHAROMYCES CEREVISIAE;

EID: 84871612321     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2244-y     Document Type: Article

References (57)

1. Friedman S, Blumberg RS. Inflammatory bowel disease. In: Kasper DL, Braunwald E, Fauci AS, et al., eds. Harrison's Principles of Internal Medicine, 16th ed. Seoul: McGraw-Hill; 2005:1776-1789.
2. Main J, McKenzie H, Yeaman GR, et al. Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. Br Med J. 1988;297:1105-1106.
3. Sendid B, Colombel JF, Jacquinot PM, et al. Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Lab Immunol. 1996;3:219-226.
4. Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn's disease into immunologically homogenous subgroups with distinct clinical characteristics. Gut. 2000; 47:487-496.
5. Vermeire S, Peeters M, Vlietinck R, et al. Anti-Saccharomyces antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis. 2001;7:8-15.
6. Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology. 1998;115:822-829.
7. Walker LJ, Aldhous MC, Drummond HE, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol. 2004;135:490-496.
8. Forcione DG, Rosen MJ, Kisiel JB, et al. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut. 2004; 53:1117-1122.
9. Arnott ID, Landers CJ, Nimmo EJ, et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol. 2004;99:2376-2384.
10. Kim BC, Park S, Han J, et al. Clinical significance of anti-Saccharomyces cerevisiae antibody (ASCA) in Korean patients with Crohn's disease and its relationship to the disease clinical course. Dig Liver Dis. 2007;39:610-616.
11. Halfvarson J, Standaert-Vitse A, Jarnerot G, et al. Anti-Saccharomyces cerevisiae antibodies in twins with inflammatory bowel disease. Gut. 2005;54:1237-1243.
12. Norman GL. Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease. Clin Appl Immunol Rev. 2001;2:45-63.
13. Hisabe T, Matsui T, Sakurai T, et al. Anti-Saccharomyces cerevisiae antibodies in Japanese patients with inflammatory bowel disease: diagnostic accuracy and clinical value. J Gastroenterol. 2003;38:121-126.
14. Suzuki H, Fukuda Y, Koizuka H, et al. Dietary antigens in Crohn's disease: antibodies to porcine pancreatic amylase. Am J Gastroenterol. 2008;103:656-664.
15. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. The Standards for Reporting of Diagnostic Accuracy Group. Croat Med J. 2003;44:635-638.
16. Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.
17. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6:8-15.
18. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-753.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
20. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
21. Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol. 2000;53:207-216.
22. Egger M, Davey Smith G, Schneider M, et al. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
23. Koutroubakis IE, Petinaki E, Mouzas IA, et al. Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Am J Gastroenterol. 2001;96:449-454.
24. Bernstein CN, Orr K, Blanchard JF, et al. Development of an assay for antibodies to Saccharomyces cerevisiae: easy, cheap and specific for Crohn's disease. Can J Gastroenterol. 2001;15:499-504.
25. Sostegni R, Daperno M, Ercole E, et al. Detection of anti-Saccharomyces cerevisiae antibodies in Crohn's disease: is it a reliable diagnostic and prognostic marker? Dig Liver Dis. 2001; 33:755-761.
26. Smith BR, Arnott ID, Drummond HE, et al. Disease location, anti-Saccharomyces cerevisiae antibody, and NOD2/CARD15 genotype influence the progression of disease behavior in Crohn's disease. Inflamm Bowel Dis. 2004;10:521-528.
27. Linskens RK, Mallant-Hent RC, Murillo LS, et al. Genetic and serological markers to identify phenotypic subgroups in a Dutch Crohn's disease population. Dig Liver Dis. 2004;36:29-34.
28. Annese V, Piepoli A, Perri F, et al. Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features. Aliment Pharmacol Ther. 2004;20:1143-1152.
29. Kaila B, Orr K, Bernstein CN. The anti-Saccharomyces cerevisiae antibody assay in a province-wide practice: accurate in identifying cases of Crohn's disease and predicting inflammatory disease. Can J Gastroenterol. 2005;19:717-721.
30. Preda CM, Diculescu M, Mirea V, et al. Significance of anti-Saccharomyces cerevisiae antibodies (ASCA) in patients with inflammatory bowel diseases in Romania. Rom J Gastroenterol. 2005;14:23-26.
31. Amre DK, Lu SE, Costea F, et al. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Am J Gastroenterol. 2006;101: 645-652.
32. Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol. 2006;101:360-367.
33. Papp M, Altorjay I, Norman GL, et al. Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients. Inflamm Bowel Dis. 2007;13:984-992.
34. Desplat-Jégo S, Johanet C, Escande A, et al. Update on anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: results of a multicenter study. World J Gastroenterol. 2007;13:2312-2318.
35. Dassopoulos T, Frangakis C, Cruz-Correa M, et al. Antibodies to Saccharomyces cerevisiae in Crohn's disease: higher titers are associated with a greater frequency of mutant NOD2/CARD15 alleles and with a higher probability of complicated disease. Inflamm Bowel Dis. 2007;13:143-151.
36. Dubinsky MC, Kugathasan S, Mei L, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol. 2008;6:1105-1111.
37. Schoepfer AM, Schaffer T, Mueller S, et al. Phenotypic associations of Crohn's disease with antibodies to flagellins A4-Fla2 and Fla-X, ASCA, p-ANCA, PAB, and NOD2 mutations in a Swiss Cohort. Inflamm Bowel Dis. 2009;15:1358-1367.
38. Solberg IC, Lygren I, Cvancarova M, et al. Predictive value of serologic markers in a population-based Norwegian cohort with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:406-414.
39. Russell RK, Ip B, Aldhous MC, et al. Anti-Saccharomyces cerevisiae antibodies status is associated with oral involvement and disease severity in Crohn disease. J Pediatr Gastroenterol Nutr. 2009;48:161-167.
40. Dassopoulos T, Nguyen GC, Talor MV, et al. NOD2 mutations and anti-Saccharomyces cerevisiae antibodies are risk factors for Crohn's disease in African Americans. Am J Gastroenterol. 2010; 105:378-386.
41. Zhou F, Xia B, Wang F, et al. The prevalence and diagnostic value of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease in mainland China. Clin Chim Acta. 2010;411:1461-1465.
42. Demirsoy H, Ozdil K, Ersoy O, et al. Anti-pancreatic antibody in Turkish patients with inflammatory bowel disease and firstdegree relatives. World J Gastroenterol. 2010;16:5732-5738.
43. Van Assche G, Rutgeerts P. Medical management of postoperative recurrence in Crohn's disease. Gastroenterol Clin North Am. 2004;33:347-360.
44. Rutgeerts P. Strategies in the prevention of post-operative recurrence in Crohn's disease. Best Pract Res Clin Gastroenterol. 2003;17:63-73.
45. Standaert-Vitse A, Jouault T, Vandewalle P, et al. Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn's disease. Gastroenterology. 2006;130:1764-1775.
46. Seibold F, Konrad A, Flogerzi B, et al. Genetic variants of the mannan-binding lectin are associated with immune reactivity to mannans in Crohn's disease. Gastroenterology. 2004;127:1076-1084.
47. Török HP, Glas J, Hollay HC, et al. Serum antibodies in firstdegree relatives of patients with IBD: a marker of disease susceptibility? A follow-up pilot-study after 7 years. Digestion. 2005;72:119-123.
48. Glas J, Török HP, Vilsmaier F, et al. Anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease and their first-degree relatives: potential clinical value. Digestion. 2002;66:173-177.
49. Papp M, Altorjay I, Dotan N, et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol. 2008;103:665-681.
50. Hugot JP, Laurent-Puig P, Gower-Rousseau C, et al. Mapping for susceptibility locus for Crohn's disease on chromosome 16. Nature. 1996;379:821-823.
51. Cruyssen BV, Peeters H, Hoffman IE, et al. CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in Caucasian Crohn's disease patients. Clin Exp Immunol. 2005;140:354-359.
52. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004;126:414-424.
53. Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology. 2002;123:679-688.
54. Henckaerts L, Pierik M, Joossens M, et al. Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. Gut. 2007; 56:1536-1542.
55. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol. 2006;12: 6102-6108.
56. Devlin SM, Yang H, Ippoliti A, et al. NOD2 variants and antibody response o microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology. 2007;132:576-586.
57. Reumaux D, Sendid B, Poulain D, et al. Serological markers in inflammatory bowel diseases. Best Pract Res Clin Gastroenterol. 2003;17:19-35.